Paul A Bunn, Jr

Title: Paul A Bunn, Jr: Innovator in Cancer Treatment Technologies

Introduction

Paul A Bunn, Jr. is a notable inventor based in Evergreen, CO (US), recognized for his significant contributions to cancer treatment technologies. He holds 5 patents that focus on methods for predicting clinical outcomes in cancer patients, particularly those undergoing treatment with epidermal growth factor receptor (EGFR) inhibitors.

Latest Patents

Bunn's latest patents include innovative methods for predicting clinical outcomes for non-small cell lung cancer patients treated with EGFR inhibitors. One of his patents discloses methods to obtain an expression score to evaluate gene expression in tissue specimens from individuals suspected of having cancer. Another patent focuses on identifying biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors. This includes methods for selecting cancer patients who may benefit from therapeutic administration of EGFR inhibitors and identifying molecules that enhance responsiveness to these treatments.

Career Highlights

Throughout his career, Paul A Bunn, Jr. has worked with esteemed organizations such as the University of Colorado and Research Corporation Technologies, Inc. His work has significantly advanced the understanding and treatment of lung cancer, making him a key figure in the field of oncology.

Collaborations

Bunn has collaborated with notable professionals in his field, including John M Stewart and Daniel C F Chan. These collaborations have contributed to the development of his innovative patents and research.

Conclusion

Paul A Bunn, Jr. is a distinguished inventor whose work in cancer treatment technologies has made a lasting impact on the medical community. His patents reflect a commitment to improving patient outcomes and advancing cancer research.